Key statistics
On Friday, Formycon AG (FYBX:GER) closed at 47.30, 25.63% above the 52 week low of 37.65 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 48.45 |
---|---|
High | 48.50 |
Low | 46.90 |
Bid | 47.30 |
Offer | 48.05 |
Previous close | 48.35 |
Average volume | 4.86k |
---|---|
Shares outstanding | 17.66m |
Free float | 11.74m |
P/E (TTM) | 11.83 |
Market cap | 835.17m EUR |
EPS (TTM) | 4.00 EUR |
Data delayed at least 15 minutes, as of Nov 08 2024 16:36 GMT.
More ▼
- EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
- EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
- Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
More ▼